Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Double Action add-on therapy in GORD patients inadequately controlled on once-daily PPI
2014-003174-17Phase 3Completed
- Sponsor
- Reckitt
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Gaviscon Double Action add-on with Matched placebo add-on (2 arms). Primary endpoint: Responder rate based on HRDQ score. Started Oct 2014; status: completed.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2014-003174-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003174-17.